Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapy

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

Zachary SteinhartMaxwell FoiseyDebolina GangulySean Yamada-HunterThe Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees.

June 28, 2024

Vol.50 No.26

In Brief

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

The Wistar Institute’s Noam Auslander, assistant professor in the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer Center, was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research.

June 28, 2024

Vol.50 No.26

In Brief

Wistar Institute receives $10M donation

The Wistar Institute received a $10 million donation from an anonymous donor who previously committed $20 million to support Wistar’s new Center for Advanced Therapeutics.

June 21, 2024

Vol.50 No.25

Clinical Roundup

Multispecific antibody shows promise for B cell lymphoma

Nutcracker Therapeutics Inc., a biotechnology company focused on developing RNA therapies through its proprietary technology platform, presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

June 14, 2024

Vol.50 No.24

In Brief

Nominate an emerging leader in IO for SITC’s Steven A. Rosenberg Scholars Award

The Society for Immunotherapy of Cancer is accepting nominations for the 2024 Steven A. Rosenberg Scholars Award, one of the society’s most prestigious opportunities for early-career scientists.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Circadian clock can be leveraged to enhance cancer immunotherapy

A multidisciplinary research team at the University of California, Irvine, has revealed that the circadian clock can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.

May 31, 2024

Vol.50 No.22

Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapy

YOU MAY BE INTERESTED IN

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

Wistar Institute receives $10M donation

Multispecific antibody shows promise for B cell lymphoma

Nominate an emerging leader in IO for SITC’s Steven A. Rosenberg Scholars Award

Circadian clock can be leveraged to enhance cancer immunotherapy

Renew today!

Subscriber content

Login